BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adinolfi LE, Rinaldi L, Nevola R. Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments? World J Gastroenterol 2018; 24(41): 4617-4621 [PMID: 30416309 DOI: 10.3748/wjg.v24.i41.4617] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramadan MS, Boccia F, Moretto SM, De Gregorio F, Gagliardi M, Iossa D, Durante-mangoni E, Zampino R. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. JCM 2022;11:5781. [DOI: 10.3390/jcm11195781] [Reference Citation Analysis]
2 Lang R, Humes E, Hogan B, Lee J, D'Agostino R, Massaro J, Kim A, Meigs JB, Borowsky L, He W, Lyass A, Cheng D, Kim HN, Klein MB, Cachay ER, Bosch RJ, Gill MJ, Silverberg MJ, Thorne JE, McGinnis K, Horberg MA, Sterling TR, Triant VA, Althoff KN. Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection. J Am Heart Assoc 2022;:e026473. [PMID: 36129038 DOI: 10.1161/JAHA.122.026473] [Reference Citation Analysis]
3 Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, Cojocariu C, Chiriac S, Cuciureanu T, Costache II, Stanciu C. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life (Basel) 2022;12:1036. [PMID: 35888123 DOI: 10.3390/life12071036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Reference Citation Analysis]
5 Hodel F, Xu ZM, Thorball CW, de La Harpe R, Letang-mathieu P, Brenner N, Butt J, Bender N, Waterboer T, Marques-vidal P, Vollenweider P, Vaucher J, Fellay J. Associations of genetic and infectious risk factors with coronary heart disease.. [DOI: 10.1101/2022.04.13.22273812] [Reference Citation Analysis]
6 Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice . World J Gastroenterol 2022; 28(12): 1226-1238 [DOI: 10.3748/wjg.v28.i12.1226] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kamalapathy PN, Sequeira S, Chen D, Bell J, Park JS, Werner BC. Postoperative Complications Following Ankle Arthrodesis in Patients With Hepatitis C: Matched Propensity Score Analysis. Foot Ankle Spec 2021;:19386400211053943. [PMID: 34711064 DOI: 10.1177/19386400211053943] [Reference Citation Analysis]
8 Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021;11:13944. [PMID: 34230541 DOI: 10.1038/s41598-021-93251-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Haykal M, Matsumori A, Saleh A, Fayez M, Negm H, Shalaby M, Bassuony S. Diagnosis and treatment of HCV heart diseases. Expert Rev Cardiovasc Ther 2021;19:493-9. [PMID: 33861939 DOI: 10.1080/14779072.2021.1917383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Husa P, Snopkova S, Zavrelova J, Zlamal F, Svacinka R, Husa P. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021;165:146-51. [PMID: 33928944 DOI: 10.5507/bp.2021.023] [Reference Citation Analysis]
12 Chan P, Spudich S. Investigating vascular diseases in people living with HIV by nuclear imaging. J Nucl Cardiol 2021. [PMID: 33884573 DOI: 10.1007/s12350-021-02613-x] [Reference Citation Analysis]
13 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bailey AL, Al-Adwan S, Sneij E, Campbell N, Wiisanen ME. Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection. Curr Cardiol Rep 2021;23:52. [PMID: 33822282 DOI: 10.1007/s11886-021-01475-6] [Reference Citation Analysis]
15 Hsiao YH, Chen WM, Chang CH, Chen MY. Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy. J Adv Nurs 2021;77:3370-8. [PMID: 33818822 DOI: 10.1111/jan.14850] [Reference Citation Analysis]
16 Eletreby R, Anees M, Naguib M, Kobtan A, Helmy A, Khalaf N, Mansour S, Hassany M, El Akel W, Hashem A, Doss W, Esmat G. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. Expert Rev Gastroenterol Hepatol 2021;15:103-10. [PMID: 32933323 DOI: 10.1080/17474124.2020.1823831] [Reference Citation Analysis]
17 Goetsch MR, Tamhane A, Overton ET, Towns GC, Franco RA. Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality. Pathog Immun 2020;5:275-90. [PMID: 33089036 DOI: 10.20411/pai.v5i1.369] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Broker M, Frager SZ, Patel NS, Lebovics E, Frishman WH. The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. Cardiol Rev 2021;29:178-83. [PMID: 32618587 DOI: 10.1097/CRD.0000000000000314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rajkumar P, Dwivedi AK, Dodoo CA, Shokar NK, Salinas J, Lakshmanaswamy R. The association between metabolic syndrome and Hepatitis C virus infection in the United States. Cancer Causes Control 2020;31:569-81. [PMID: 32300943 DOI: 10.1007/s10552-020-01300-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Singh N, Rai S, Bhatnagar R, Bhatnagar S. Network analysis of host-pathogen protein interactions in microbe induced cardiovascular diseases. In Silico Biol 2020;14:115-33. [PMID: 35001887 DOI: 10.3233/ISB-210238] [Reference Citation Analysis]
21 Abd El Hafez MA, Kasemy ZAA. Effect of direct-acting antivirals on platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with hepatitis C virus-related thrombocytopenia. Egypt J Intern Med 2019;31:296-301. [DOI: 10.4103/ejim.ejim_14_19] [Reference Citation Analysis]